Administration of Crushed Doravirine via Nasojejunal Feeding Tube in a Patient With Treatment-Experienced Human Immunodeficiency Virus

Walker CK Shaw CM Moss Perry MV , . Antiretroviral therapy management in adults with HIV during ICU admission. J Pharm Pract 2021;8971900211000692. doi:10.1177/08971900211000692. Online ahead of Print.

Pifeltro Package Insert. Whitehouse Station, NJ: Merck & Co., Inc; 2018.

Panel on Antiretroviral Guidelines for Adults and Adolescents . Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Washington, DC: Department of Health and Human Services; 2021. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf. Accessed 20 September, 2021.

Turley SL Fulco PP . Enteral administration of twice-daily dolutegravir and rilpivirine as a part of a triple-therapy regimen in a critically ill patient with HIV. J Int Assoc Phys AIDS Care. 2017;16:117-119.

Pretorius E Klinker H Rosenkranz B . The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus. Ther Drug Monit. 2011;33:265-274.

Tebano G Soulie C Schneider L , et al. Long-term follow up of HIV-infected patients on dolutegravir monotherapy. J Antimicrob Chemother. 2020;75:675-680.

Gallant J Sugarman J . Dolutegravir monotherapy: When should clinical practice be clinical research? Antivir Ther. 2017;22:93-95.

Li JZ Etemad B Ahmed H , et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS. 2016;30:343-353.

Conway CM Perelson AS Li JZ . Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers. PLoS Comput Biol. 2019;15:e1007229.

Deeks SG Lewis SR Ross AL , et al. International AIDS Society global scientific strategy: Towards an HIV cure 2016. Nat Med. 2021;27:2085-2098.

Llibre JM Hung CC Brinson C , et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: Phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391:839-849.

Paton NI Musaazi J Kityo C , et al. Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV. N Engl J Med. 2021;385:330-341.